Drug reference
Talazoparib is a PARP inhibitor. PARP are enzymes that repair damaged DNA in cancer cells and, in the absence of functional BRCA, inhibition of PARP results in an inability of cancer cells to repair. Therefore inhibition of PARP results in an antineoplastic effect.
PDF page 1087
Breast cancer (initiated by a specialist) ▶BY MOUTH ▶Adult: 1 mg once daily, for dose adjustments due to side-effects—consult product literature
PDF page 1087
DUE TO INTERACTIONS ▶Manufacturer advises if concomitant use with P- glycoprotein inhibitors is unavoidable, reduce dose to 750 micrograms once daily.
PDF page 1087
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.
PDF page 1087
→Appendix 1: talazoparib
PDF page 1087
▶Common or very common Alopecia. anaemia. appetite decreased. asthenia. decreased leucocytes. diarrhoea. dizziness. gastrointestinal discomfort. headache. nausea. neutropenia. stomatitis. taste altered. thrombocytopenia . vomiting ▶Frequency not known Bone marrow depression. neoplasms
PDF page 1087
Manufacturer advises effective contraception in women of childbearing potential during treatment and for 7 months after receiving the last dose. Male patients should use effective contraception during and for at least 4 months after treatment if their Immune system and malignant disease partner is pregnant or of childbearing potential. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 1087
Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 1087
Manufacturer advises avoid during treatment and for 1 month after last dose—no information available.
PDF page 1087
Manufacturer advises avoid in moderate or severe impairment unless benefit outweighs risk (no information available).
PDF page 1087
Manufacturer advises avoid if creatinine clearance less than 30 mL/minute unless benefit outweighs risk (no information available). Dose adjustments Manufacturer advises reduce starting dose to 750 micrograms once daily if creatinine clearance 30–60 mL/minute.
PDF page 1087
Manufacturer advises monitor full blood count before treatment initiation, then monthly thereafter and as clinically indicated.
PDF page 1087
There can be variation in the licensing of different medicines containing the same drug. Capsule CAUTIONARY AND ADVISORY LABELS 25 A ▶Talzenna (Pfizer Ltd) Talazoparib (as Talazoparib tosylate) 250 microgram Talzenna 0.25mg capsules | 30 capsule P £1,655.00 (Hospital only) Talazoparib (as Talazoparib tosylate) 1 mg Talzenna 1mg capsules | 30 capsule P £4,965.00 (Hospital only)
PDF page 1087
Driving and skilled tasks Manufacturer advises patients and their carers should be counselled on the effects on driving and skilled tasks—increased risk of fatigue and dizziness.
PDF page 1087
1 mg once daily, for dose adjustments due to
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1087
